img

Global Novel Coronavirus (COVID-19) Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application


Published on: 2024-01-04 | No of Pages : 400 | Industry : Latest Trends

Publisher : MRA | Format : PDF

Global Novel Coronavirus (COVID-19) Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Novel Coronavirus (COVID-19) Vaccine report published by MRA Research reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2023. Global Novel Coronavirus (COVID-19) Vaccine market is projected to reach US$ million in 2033, increasing from US$ million in 2023, with the CAGR of % during the period of 2023 to 2033. Demand from Mild Symptom Patient and Critically Ill Patient are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2023, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2023. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2023. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2023) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Novel Coronavirus (COVID-19) Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise
Segment by Type
DNA
RNA
Others

Segment by Application


Mild Symptom Patient
Critically Ill Patient
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Novel Coronavirus (COVID-19) Vaccine market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Novel Coronavirus (COVID-19) Vaccine introduction, etc. Novel Coronavirus (COVID-19) Vaccine Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRA Research’s Conclusions of Novel Coronavirus (COVID-19) Vaccine market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRA Research.

Table of Content

1 Market Overview of Novel Coronavirus (COVID-19) Vaccine
1.1 Novel Coronavirus (COVID-19) Vaccine Market Overview
1.1.1 Novel Coronavirus (COVID-19) Vaccine Product Scope
1.1.2 Novel Coronavirus (COVID-19) Vaccine Market Status and Outlook
1.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size Overview by Region 2018 VS 2023 VS 2033
1.3 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2018-2033)
1.4 Global Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Region (2018-2023)
1.5 Global Novel Coronavirus (COVID-19) Vaccine Market Size Forecast by Region (2024-2033)
1.6 Key Regions, Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033)
1.6.1 North America Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033)
1.6.2 Europe Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033)
1.6.3 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033)
1.6.4 Latin America Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033)
1.6.5 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033)
2 Novel Coronavirus (COVID-19) Vaccine Market by Type
2.1 Introduction
2.1.1 DNA
2.1.2 RNA
2.1.3 Others
2.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type: 2018 VS 2023 VS 2033
2.2.1 Global Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Type (2018-2023)
2.2.2 Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Type (2024-2033)
2.3 Key Regions Market Size by Type
2.3.1 North America Novel Coronavirus (COVID-19) Vaccine Revenue Breakdown by Type (2018-2033)
2.3.2 Europe Novel Coronavirus (COVID-19) Vaccine Revenue Breakdown by Type (2018-2033)
2.3.3 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Breakdown by Type (2018-2033)
2.3.4 Latin America Novel Coronavirus (COVID-19) Vaccine Revenue Breakdown by Type (2018-2033)
2.3.5 Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Breakdown by Type (2018-2033)
3 Novel Coronavirus (COVID-19) Vaccine Market Overview by Application
3.1 Introduction
3.1.1 Mild Symptom Patient
3.1.2 Critically Ill Patient
3.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application: 2018 VS 2023 VS 2033
3.2.1 Global Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Application (2018-2023)
3.2.2 Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Application (2024-2033)
3.3 Key Regions Market Size by Application
3.3.1 North America Novel Coronavirus (COVID-19) Vaccine Revenue Breakdown by Application (2018-2033)
3.3.2 Europe Novel Coronavirus (COVID-19) Vaccine Revenue Breakdown by Application (2018-2033)
3.3.3 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Breakdown by Application (2018-2033)
3.3.4 Latin America Novel Coronavirus (COVID-19) Vaccine Revenue Breakdown by Application (2018-2033)
3.3.5 Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Breakdown by Application (2018-2033)
4 Novel Coronavirus (COVID-19) Vaccine Competition Analysis by Players
4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Novel Coronavirus (COVID-19) Vaccine as of 2023)
4.3 Date of Key Players Enter into Novel Coronavirus (COVID-19) Vaccine Market
4.4 Global Top Players Novel Coronavirus (COVID-19) Vaccine Headquarters and Area Served
4.5 Key Players Novel Coronavirus (COVID-19) Vaccine Product Solution and Service
4.6 Competitive Status
4.6.1 Novel Coronavirus (COVID-19) Vaccine Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Inovio Pharmaceuticals
5.1.1 Inovio Pharmaceuticals Profile
5.1.2 Inovio Pharmaceuticals Main Business
5.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.1.4 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.1.5 Inovio Pharmaceuticals Recent Developments
5.2 Takis Biotech (Evvivax)
5.2.1 Takis Biotech (Evvivax) Profile
5.2.2 Takis Biotech (Evvivax) Main Business
5.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.2.4 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.2.5 Takis Biotech (Evvivax) Recent Developments
5.3 Zydus Cadila
5.3.1 Zydus Cadila Profile
5.3.2 Zydus Cadila Main Business
5.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.3.4 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.3.5 Codagenix, Inc. Recent Developments
5.4 Codagenix, Inc.
5.4.1 Codagenix, Inc. Profile
5.4.2 Codagenix, Inc. Main Business
5.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.4.4 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.4.5 Codagenix, Inc. Recent Developments
5.5 GeoVax, Inc.
5.5.1 GeoVax, Inc. Profile
5.5.2 GeoVax, Inc. Main Business
5.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.5.4 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.5.5 GeoVax, Inc. Recent Developments
5.6 Bravovax
5.6.1 Bravovax Profile
5.6.2 Bravovax Main Business
5.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.6.4 Bravovax Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.6.5 Bravovax Recent Developments
5.7 Janssen Pharmaceutical Companies
5.7.1 Janssen Pharmaceutical Companies Profile
5.7.2 Janssen Pharmaceutical Companies Main Business
5.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.7.4 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.7.5 Janssen Pharmaceutical Companies Recent Developments
5.8 Altimmune
5.8.1 Altimmune Profile
5.8.2 Altimmune Main Business
5.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.8.4 Altimmune Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.8.5 Altimmune Recent Developments
5.9 Vaxart
5.9.1 Vaxart Profile
5.9.2 Vaxart Main Business
5.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.9.4 Vaxart Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.9.5 Vaxart Recent Developments
5.10 CanSino Biologics
5.10.1 CanSino Biologics Profile
5.10.2 CanSino Biologics Main Business
5.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.10.4 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.10.5 CanSino Biologics Recent Developments
5.11 ExpreS2ion Biotechnologies ApS
5.11.1 ExpreS2ion Biotechnologies ApS Profile
5.11.2 ExpreS2ion Biotechnologies ApS Main Business
5.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.11.4 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.11.5 ExpreS2ion Biotechnologies ApS Recent Developments
5.12 Clover Biopharmaceuticals
5.12.1 Clover Biopharmaceuticals Profile
5.12.2 Clover Biopharmaceuticals Main Business
5.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.12.4 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.12.5 Clover Biopharmaceuticals Recent Developments
5.13 GSK
5.13.1 GSK Profile
5.13.2 GSK Main Business
5.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.13.4 GSK Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.13.5 GSK Recent Developments
5.14 Vaxil Bio Ltd.
5.14.1 Vaxil Bio Ltd. Profile
5.14.2 Vaxil Bio Ltd. Main Business
5.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.14.4 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.14.5 Vaxil Bio Ltd. Recent Developments
5.15 Generex
5.15.1 Generex Profile
5.15.2 Generex Main Business
5.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.15.4 Generex Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.15.5 Generex Recent Developments
5.16 Novavax, Inc.
5.16.1 Novavax, Inc. Profile
5.16.2 Novavax, Inc. Main Business
5.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.16.4 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.16.5 Novavax, Inc. Recent Developments
5.17 Sanofi Pasteur
5.17.1 Sanofi Pasteur Profile
5.17.2 Sanofi Pasteur Main Business
5.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.17.4 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.17.5 Sanofi Pasteur Recent Developments
5.18 Baylor
5.18.1 Baylor Profile
5.18.2 Baylor Main Business
5.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.18.4 Baylor Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.18.5 Baylor Recent Developments
5.19 iBio, Inc.
5.19.1 iBio, Inc. Profile
5.19.2 iBio, Inc. Main Business
5.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.19.4 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.19.5 iBio, Inc. Recent Developments
5.20 Moderna, Inc.
5.20.1 Moderna, Inc. Profile
5.20.2 Moderna, Inc. Main Business
5.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.20.4 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.20.5 Moderna, Inc. Recent Developments
5.21 Curevac
5.21.1 Curevac Profile
5.21.2 Curevac Main Business
5.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.21.4 Curevac Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.21.5 Curevac Recent Developments
5.22 ImmunoPrecise
5.22.1 ImmunoPrecise Profile
5.22.2 ImmunoPrecise Main Business
5.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
5.22.4 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2018-2023)
5.22.5 ImmunoPrecise Recent Developments
6 North America
6.1 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2033)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2033)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2018-2033)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2033)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2033)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Novel Coronavirus (COVID-19) Vaccine Market Dynamics
11.1 Novel Coronavirus (COVID-19) Vaccine Industry Trends
11.2 Novel Coronavirus (COVID-19) Vaccine Market Drivers
11.3 Novel Coronavirus (COVID-19) Vaccine Market Challenges
11.4 Novel Coronavirus (COVID-19) Vaccine Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Novel Coronavirus (COVID-19) Vaccine Market Size (US$ Million) Comparison by Region 2018 VS 2023 VS 2033
Table 2. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 3. Global Novel Coronavirus (COVID-19) Vaccine Market Size Share by Region (2018-2023)
Table 4. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 5. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size Share by Region (2024-2033)
Table 6. Global Novel Coronavirus (COVID-19) Vaccine Market Size (US$ Million) by Type: 2018 VS 2023 VS 2033
Table 7. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 8. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2023)
Table 9. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 10. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2024-2033)
Table 11. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 12. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2024-2033) & (US$ Million)
Table 13. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 14. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2024-2033) & (US$ Million)
Table 15. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 16. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2024-2033) & (US$ Million)
Table 17. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 18. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2024-2033) & (US$ Million)
Table 19. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 20. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2024-2033) & (US$ Million)
Table 21. Global Novel Coronavirus (COVID-19) Vaccine Market Size (US$ Million) by Application: 2018 VS 2023 VS 2033
Table 22. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2023)
Table 24. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 25. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2024-2033)
Table 26. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 27. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2024-2033) & (US$ Million)
Table 28. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 29. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2024-2033) & (US$ Million)
Table 30. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 31. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2024-2033) & (US$ Million)
Table 32. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 33. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2024-2033) & (US$ Million)
Table 34. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 35. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2024-2033) & (US$ Million)
Table 36. Global Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) by Players (2018-2023)
Table 37. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Players (2018-2023)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Novel Coronavirus (COVID-19) Vaccine as of 2023)
Table 39. Date of Key Players Enter into Novel Coronavirus (COVID-19) Vaccine Market
Table 40. Global Novel Coronavirus (COVID-19) Vaccine Key Players Headquarters and Area Served
Table 41. Novel Coronavirus (COVID-19) Vaccine Product Solution and Service
Table 42. Global Novel Coronavirus (COVID-19) Vaccine Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Inovio Pharmaceuticals Basic Information List
Table 45. Inovio Pharmaceuticals Description and Business Overview
Table 46. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 47. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Inovio Pharmaceuticals (2018-2023)
Table 48. Inovio Pharmaceuticals Recent Developments
Table 49. Takis Biotech (Evvivax) Basic Information List
Table 50. Takis Biotech (Evvivax) Description and Business Overview
Table 51. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 52. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Takis Biotech (Evvivax) (2018-2023)
Table 53. Takis Biotech (Evvivax) Recent Developments
Table 54. Zydus Cadila Basic Information List
Table 55. Zydus Cadila Description and Business Overview
Table 56. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 57. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Zydus Cadila (2018-2023)
Table 58. Zydus Cadila Recent Developments
Table 59. Codagenix, Inc. Basic Information List
Table 60. Codagenix, Inc. Description and Business Overview
Table 61. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 62. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Codagenix, Inc. (2018-2023)
Table 63. Codagenix, Inc. Recent Developments
Table 64. GeoVax, Inc. Basic Information List
Table 65. GeoVax, Inc. Description and Business Overview
Table 66. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 67. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of GeoVax, Inc. (2018-2023)
Table 68. GeoVax, Inc. Recent Developments
Table 69. Bravovax Basic Information List
Table 70. Bravovax Description and Business Overview
Table 71. Bravovax Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 72. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Bravovax (2018-2023)
Table 73. Bravovax Recent Developments
Table 74. Janssen Pharmaceutical Companies Basic Information List
Table 75. Janssen Pharmaceutical Companies Description and Business Overview
Table 76. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 77. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Janssen Pharmaceutical Companies (2018-2023)
Table 78. Janssen Pharmaceutical Companies Recent Developments
Table 79. Altimmune Basic Information List
Table 80. Altimmune Description and Business Overview
Table 81. Altimmune Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 82. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Altimmune (2018-2023)
Table 83. Altimmune Recent Developments
Table 84. Vaxart Basic Information List
Table 85. Vaxart Description and Business Overview
Table 86. Vaxart Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 87. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Vaxart (2018-2023)
Table 88. Vaxart Recent Developments
Table 89. CanSino Biologics Basic Information List
Table 90. CanSino Biologics Description and Business Overview
Table 91. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 92. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of CanSino Biologics (2018-2023)
Table 93. CanSino Biologics Recent Developments
Table 94. ExpreS2ion Biotechnologies ApS Basic Information List
Table 95. ExpreS2ion Biotechnologies ApS Description and Business Overview
Table 96. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 97. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of ExpreS2ion Biotechnologies ApS (2018-2023)
Table 98. ExpreS2ion Biotechnologies ApS Recent Developments
Table 99. Clover Biopharmaceuticals Basic Information List
Table 100. Clover Biopharmaceuticals Description and Business Overview
Table 101. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 102. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Clover Biopharmaceuticals (2018-2023)
Table 103. Clover Biopharmaceuticals Recent Developments
Table 104. GSK Basic Information List
Table 105. GSK Description and Business Overview
Table 106. GSK Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 107. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of GSK (2018-2023)
Table 108. GSK Recent Developments
Table 109. Vaxil Bio Ltd. Basic Information List
Table 110. Vaxil Bio Ltd. Description and Business Overview
Table 111. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 112. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Vaxil Bio Ltd. (2018-2023)
Table 113. Vaxil Bio Ltd. Recent Developments
Table 114. Generex Basic Information List
Table 115. Generex Description and Business Overview
Table 116. Generex Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 117. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Generex (2018-2023)
Table 118. Generex Recent Developments
Table 119. Novavax, Inc. Basic Information List
Table 120. Novavax, Inc. Description and Business Overview
Table 121. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 122. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Novavax, Inc. (2018-2023)
Table 123. Novavax, Inc. Recent Developments
Table 124. Sanofi Pasteur Basic Information List
Table 125. Sanofi Pasteur Description and Business Overview
Table 126. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 127. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Sanofi Pasteur (2018-2023)
Table 128. Sanofi Pasteur Recent Developments
Table 129. Baylor Basic Information List
Table 130. Baylor Description and Business Overview
Table 131. Baylor Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 132. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Baylor (2018-2023)
Table 133. Baylor Recent Developments
Table 134. iBio, Inc. Basic Information List
Table 135. iBio, Inc. Description and Business Overview
Table 136. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 137. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of iBio, Inc. (2018-2023)
Table 138. iBio, Inc. Recent Developments
Table 139. Moderna, Inc. Basic Information List
Table 140. Moderna, Inc. Description and Business Overview
Table 141. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 142. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Moderna, Inc. (2018-2023)
Table 143. Moderna, Inc. Recent Developments
Table 144. Curevac Basic Information List
Table 145. Curevac Description and Business Overview
Table 146. Curevac Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 147. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Curevac (2018-2023)
Table 148. Curevac Recent Developments
Table 149. ImmunoPrecise Basic Information List
Table 150. ImmunoPrecise Description and Business Overview
Table 151. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
Table 152. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of ImmunoPrecise (2018-2023)
Table 153. ImmunoPrecise Recent Developments
Table 154. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 155. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 156. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 157. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 158. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2023 VS 2033
Table 159. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 160. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2024-2033) & (US$ Million)
Table 161. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Share by Region (2018-2023)
Table 162. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Share by Region (2024-2033)
Table 163. Latin America Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2023 VS 2033
Table 164. Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 165. Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 166. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2023 VS 2033
Table 167. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 168. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 169. Novel Coronavirus (COVID-19) Vaccine Market Trends
Table 170. Novel Coronavirus (COVID-19) Vaccine Market Drivers
Table 171. Novel Coronavirus (COVID-19) Vaccine Market Challenges
Table 172. Novel Coronavirus (COVID-19) Vaccine Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Novel Coronavirus (COVID-19) Vaccine Market Size Year-over-Year 2018-2033 & (US$ Million)
Figure 2. Global Novel Coronavirus (COVID-19) Vaccine Market Size (US$ Million), 2018 VS 2023 VS 2033
Figure 3. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Regions: 2023 VS 2033
Figure 4. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size Share by Region (2024-2033)
Figure 5. North America Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 6. Europe Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 7. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 8. Latin America Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 9. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 10. Product Picture of DNA
Figure 11. Global DNA Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 12. Product Picture of RNA
Figure 13. Global RNA Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 14. Product Picture of Others
Figure 15. Global Others Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 16. Global Novel Coronavirus (COVID-19) Vaccine Market Size Share by Type: 2023 & 2033
Figure 17. North America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2033)
Figure 18. Europe Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2033)
Figure 19. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2033)
Figure 20. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2033)
Figure 21. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2033)
Figure 22. Mild Symptom Patient Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 23. Critically Ill Patient Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 24. Global Novel Coronavirus (COVID-19) Vaccine Market Size Share by Application: 2023 & 2033
Figure 25. North America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2033)
Figure 26. Europe Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2033)
Figure 27. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2033)
Figure 28. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2033)
Figure 29. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2033)
Figure 30. Novel Coronavirus (COVID-19) Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2023
Figure 31. Global Top 5 and Top 10 Players Novel Coronavirus (COVID-19) Vaccine Market Share in 2023
Figure 32. North America Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2018-2033)
Figure 33. United States Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 34. Canada Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 35. Germany Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 36. France Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 37. U.K. Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 38. Italy Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 39. Russia Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 40. Nordic Countries Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 41. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Share by Region (2018-2033)
Figure 42. China Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 43. Japan Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 44. South Korea Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 45. Southeast Asia Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 46. India Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 47. Australia Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 48. Latin America Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2018-2033)
Figure 49. Mexico Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 50. Brazil Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 51. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2018-2033)
Figure 52. Turkey Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 53. Saudi Arabia Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 54. UAE Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033) & (US$ Million)
Figure 55. Bottom-up and Top-down Approaches for This Report